NASDAQ:XENT - Intersect ENT Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$39.30 -0.05 (-0.13 %)
(As of 05/24/2018 04:00 PM ET)
Previous Close$39.35
Today's Range$38.55 - $39.45
52-Week Range$23.24 - $42.25
Volume457,500 shs
Average Volume278,883 shs
Market Capitalization$1.19 billion
P/E Ratio-70.18
Dividend YieldN/A
Beta0.75

About Intersect ENT (NASDAQ:XENT)

Intersect ENT logoIntersect ENT, Inc., a drug delivery company, researches and develops products for the treatment of patients with ear, nose and throat conditions in the United States. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. The company is also developing SINUVA, a steroid releasing implant for refractory disease for the treatment of patients in the physician office setting. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was founded in 2003 and is headquartered in Menlo Park, California.

Receive XENT News and Ratings via Email

Sign-up to receive the latest news and ratings for XENT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:XENT
CUSIPN/A
Phone650-641-2100

Debt

Debt-to-Equity RatioN/A
Current Ratio8.99
Quick Ratio8.39

Price-To-Earnings

Trailing P/E Ratio-70.18
Forward P/E Ratio-61.41
P/E GrowthN/A

Sales & Book Value

Annual Sales$96.30 million
Price / Sales12.30
Cash FlowN/A
Price / CashN/A
Book Value$3.93 per share
Price / Book10.00

Profitability

EPS (Most Recent Fiscal Year)($0.56)
Net Income$-16,360,000.00
Net Margins-15.73%
Return on Equity-13.67%
Return on Assets-12.06%

Miscellaneous

Employees327
Outstanding Shares30,140,000

Intersect ENT (NASDAQ:XENT) Frequently Asked Questions

What is Intersect ENT's stock symbol?

Intersect ENT trades on the NASDAQ under the ticker symbol "XENT."

How were Intersect ENT's earnings last quarter?

Intersect ENT (NASDAQ:XENT) issued its quarterly earnings results on Tuesday, May, 1st. The medical equipment provider reported ($0.21) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.23) by $0.02. The medical equipment provider had revenue of $24.70 million for the quarter, compared to the consensus estimate of $23.66 million. Intersect ENT had a negative return on equity of 13.67% and a negative net margin of 15.73%. The company's revenue for the quarter was up 20.5% on a year-over-year basis. During the same period in the previous year, the business posted ($0.23) EPS. View Intersect ENT's Earnings History.

When is Intersect ENT's next earnings date?

Intersect ENT is scheduled to release their next quarterly earnings announcement on Monday, July, 30th 2018. View Earnings Estimates for Intersect ENT.

What price target have analysts set for XENT?

9 analysts have issued 12-month target prices for Intersect ENT's stock. Their forecasts range from $31.00 to $48.00. On average, they anticipate Intersect ENT's stock price to reach $37.5714 in the next twelve months. View Analyst Ratings for Intersect ENT.

What are Wall Street analysts saying about Intersect ENT stock?

Here are some recent quotes from research analysts about Intersect ENT stock:
  • 1. Canaccord Genuity analysts commented, "We reiterate our BUY rating on XENT and view ongoing share weakness as a buying opportunity. Specifically, shares are down ~9% intraday following the release of preliminary CMS guidelines that deny XENT’s request for a standalone J-code for Sinuva. The decision was disclosed in the CMS preliminary agenda for the upcoming Public Meeting for Drugs, Biological, and Radiopharmaceuticals held on May 15, 2018 (link). In the preliminary guideline CMS denies XENT’s request for a product-specific J-code and instead assigns Sinuva to an old and soon to be defunct (as of Jan 1, 2019) Category 3 CPT code – 0406T. Our conversation with management suggests the decision in the preliminary guidelines was likely an oversight on the part of CMS and something that will likely be addressed when the topic presented at the meeting on May 15." (5/7/2018)
  • 2. According to Zacks Investment Research, "Intersect ENT, Inc. is a commercial drug-device company. The Company's initial products, PROPEL and PROPEL mini, are drug-eluting implants for use in patients with chronic sinusitis. It offers products and therapies for ear, nose, and throat surgeons to improve treatment for their patients with chronic diseases. Intersect ENT, Inc. is headquartered in Menlo Park, California. " (5/5/2018)
  • 3. Northland Securities analysts commented, "We are raising our FY18 and FY19 numbers, in part due to elevated expectations on SINUVA. In our view, this story of marginal beats and managing Street expectations" is not enough to elevate the stock from its current 10x sales multiple." (5/2/2018)

Who are some of Intersect ENT's key competitors?

Who are Intersect ENT's key executives?

Intersect ENT's management team includes the folowing people:
  • Ms. Lisa D. Earnhardt, Chief Exec. Officer, Pres and Director (Age 48)
  • Ms. Jeryl L. Hilleman M.B.A, Chief Financial Officer (Age 60)
  • Mr. Richard E. Kaufman, Chief Operating Officer (Age 56)
  • Mr. David A. Lehman, Gen. Counsel & Sec. (Age 57)
  • Ms. Gwen R. Carscadden, Chief People Officer (Age 57)

Has Intersect ENT been receiving favorable news coverage?

Media headlines about XENT stock have been trending somewhat positive recently, according to Accern. Accern identifies positive and negative news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Intersect ENT earned a news sentiment score of 0.17 on Accern's scale. They also assigned press coverage about the medical equipment provider an impact score of 46.43 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

Who are Intersect ENT's major shareholders?

Intersect ENT's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.43%), Federated Investors Inc. PA (2.93%), Neuberger Berman Group LLC (1.77%), Rock Springs Capital Management LP (1.36%), Lord Abbett & CO. LLC (1.28%) and Northern Trust Corp (1.18%). Company insiders that own Intersect ENT stock include Amy Wolbeck, David Aaron Lehman, Frederic H Moll, Gwen R Carscadden, James Stambaugh, Jeryl L Hilleman, Lisa D Earnhardt and Richard E Kaufman. View Institutional Ownership Trends for Intersect ENT.

Which institutional investors are selling Intersect ENT stock?

XENT stock was sold by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, Neuberger Berman Group LLC, Citigroup Inc., Millennium Management LLC, BlackRock Inc., GSA Capital Partners LLP, Tiverton Asset Management LLC and A.R.T. Advisors LLC. Company insiders that have sold Intersect ENT company stock in the last year include David Aaron Lehman, Frederic H Moll, Gwen R Carscadden, Jeryl L Hilleman, Lisa D Earnhardt and Richard E Kaufman. View Insider Buying and Selling for Intersect ENT.

Which institutional investors are buying Intersect ENT stock?

XENT stock was bought by a variety of institutional investors in the last quarter, including Matarin Capital Management LLC, Public Employees Retirement Association of Colorado, Loomis Sayles & Co. L P, Royal Bank of Canada, Bamco Inc. NY, Sivik Global Healthcare LLC, Rock Springs Capital Management LP and Thrivent Financial for Lutherans. View Insider Buying and Selling for Intersect ENT.

How do I buy shares of Intersect ENT?

Shares of XENT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Intersect ENT's stock price today?

One share of XENT stock can currently be purchased for approximately $39.30.

How big of a company is Intersect ENT?

Intersect ENT has a market capitalization of $1.19 billion and generates $96.30 million in revenue each year. The medical equipment provider earns $-16,360,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis. Intersect ENT employs 327 workers across the globe.

How can I contact Intersect ENT?

Intersect ENT's mailing address is 1555 ADAMS DRIVE, MENLO PARK CA, 94025. The medical equipment provider can be reached via phone at 650-641-2100 or via email at [email protected]


MarketBeat Community Rating for Intersect ENT (XENT)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  265 (Vote Outperform)
Underperform Votes:  143 (Vote Underperform)
Total Votes:  408
MarketBeat's community ratings are surveys of what our community members think about Intersect ENT and other stocks. Vote "Outperform" if you believe XENT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XENT will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Intersect ENT (NASDAQ:XENT) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
9 Wall Street analysts have issued ratings and price targets for Intersect ENT in the last 12 months. Their average twelve-month price target is $37.5714, suggesting that the stock has a possible downside of 4.40%. The high price target for XENT is $48.00 and the low price target for XENT is $31.00. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.782.822.802.78
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $37.5714$33.4286$33.4286$30.5714
Price Target Upside: 4.40% downside20.26% downside3.17% upside7.27% upside

Intersect ENT (NASDAQ:XENT) Consensus Price Target History

Price Target History for Intersect ENT (NASDAQ:XENT)

Intersect ENT (NASDAQ:XENT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/7/2018Canaccord GenuityReiterated RatingBuyLowView Rating Details
5/2/2018Northland SecuritiesReiterated RatingHold$32.00LowView Rating Details
5/2/2018BTIG ResearchReiterated RatingHoldLowView Rating Details
5/2/2018JPMorgan Chase & Co.Reiterated RatingOverweight$48.00LowView Rating Details
4/20/2018Berenberg BankInitiated CoverageBuyLowView Rating Details
3/1/2018GuggenheimReiterated RatingBuyLowView Rating Details
9/11/2017Bank of AmericaBoost Price TargetBuy$33.00 ➝ $40.00HighView Rating Details
8/22/2017Piper Jaffray CompaniesReiterated RatingBuy$35.00LowView Rating Details
8/2/2017Deutsche BankSet Price TargetBuy$27.00 ➝ $31.00HighView Rating Details
5/10/2017William BlairReiterated RatingOutperformLowView Rating Details
5/3/2017WedbushBoost Price TargetOutperform ➝ Outperform$25.00 ➝ $26.00HighView Rating Details
11/4/2016Leerink SwannReiterated RatingOutperform$21.00 ➝ $14.00N/AView Rating Details
(Data available from 5/24/2016 forward)

Earnings

Intersect ENT (NASDAQ:XENT) Earnings History and Estimates Chart

Earnings by Quarter for Intersect ENT (NASDAQ:XENT)

Intersect ENT (NASDAQ:XENT) Earnings Estimates

2018 EPS Consensus Estimate: ($0.65)
2019 EPS Consensus Estimate: ($0.44)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.20)($0.18)($0.19)
Q2 20183($0.20)($0.15)($0.17)
Q3 20182($0.18)($0.14)($0.16)
Q4 20183($0.14)($0.11)($0.13)
Q1 20192($0.16)($0.16)($0.16)
Q2 20191($0.11)($0.11)($0.11)
Q3 20192($0.11)($0.07)($0.09)
Q4 20192($0.08)($0.07)($0.08)

Intersect ENT (NASDAQ XENT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/30/2018($0.15)N/AView Earnings Details
5/1/2018Q1 2018($0.23)($0.21)$23.66 million$24.70 millionViewN/AView Earnings Details
2/27/2018Q4 2017($0.17)($0.11)$29.45 million$29.53 millionViewListenView Earnings Details
11/2/2017Q3 2017($0.20)($0.15)$21.53 million$22.31 millionViewN/AView Earnings Details
8/1/2017Q2 2017($0.1870)($0.08)$22.62 million$24.00 millionViewListenView Earnings Details
5/2/2017Q1 2017($0.25)($0.23)$19.39 million$20.47 millionViewListenView Earnings Details
2/28/2017Q416($0.20)($0.17)$23.47 million$24.20 millionViewListenView Earnings Details
11/2/2016Q316($0.27)($0.22)$17.80 million$18.50 millionViewN/AView Earnings Details
8/2/2016Q216($0.26)($0.21)$18.91 million$19.30 millionViewN/AView Earnings Details
5/5/2016Q116($0.29)($0.29)$16.92 million$16.69 millionViewN/AView Earnings Details
2/23/2016Q415($0.25)($0.20)$18.36 million$18.80 millionViewListenView Earnings Details
11/4/2015Q315($0.29)($0.35)$14.80 million$14.20 millionViewN/AView Earnings Details
8/5/2015Q215($0.26)($0.23)$14.74 million$15.20 millionViewN/AView Earnings Details
5/6/2015Q115($0.33)($0.23)$13.00 million$13.37 millionViewN/AView Earnings Details
2/26/2015Q414($0.29)($0.16)$12.20 million$13.40 millionViewN/AView Earnings Details
11/5/2014Q314($0.35)($0.32)$8.20 million$9.10 millionViewN/AView Earnings Details
9/3/2014Q2 2014($0.28)($2.36)$8.33 million$8.57 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Intersect ENT (NASDAQ:XENT) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Intersect ENT (NASDAQ XENT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.90%
Institutional Ownership Percentage: 88.95%
Insider Trading History for Intersect ENT (NASDAQ:XENT)
Institutional Ownership by Quarter for Intersect ENT (NASDAQ:XENT)

Intersect ENT (NASDAQ XENT) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/3/2018Jeryl L HillemanCFOSell12,833$39.94$512,550.0236,265View SEC Filing  
4/16/2018Lisa D EarnhardtInsiderSell15,000$39.59$593,850.00499,683View SEC Filing  
4/3/2018Jeryl L HillemanCFOSell12,833$37.66$483,290.7836,265View SEC Filing  
3/15/2018Lisa D EarnhardtInsiderSell15,000$38.32$574,800.00499,683View SEC Filing  
3/6/2018Jeryl L HillemanCFOSell12,833$35.92$460,961.3636,265View SEC Filing  
2/15/2018Lisa D EarnhardtInsiderSell15,000$36.40$546,000.00499,683View SEC Filing  
2/6/2018Jeryl L HillemanCFOSell12,833$35.80$459,421.4025,765View SEC Filing  
2/1/2018Richard E KaufmanCOOSell958$37.21$35,647.1887,512View SEC Filing  
1/18/2018Lisa D EarnhardtInsiderSell11,166$33.47$373,726.02495,849View SEC Filing  
1/17/2018Richard E KaufmanCOOSell50,000$33.33$1,666,500.00107,470View SEC Filing  
1/12/2018Gwen R CarscaddenInsiderSell10,000$34.35$343,500.0013,856View SEC Filing  
1/11/2018Jeryl L HillemanCFOSell12,835$33.81$433,951.3525,767View SEC Filing  
12/15/2017Lisa D EarnhardtInsiderSell10,685$31.87$340,530.95487,868View SEC Filing  
12/11/2017David Aaron LehmanGeneral CounselSell36,000$32.75$1,179,000.0045,000View SEC Filing  
12/4/2017Jeryl L HillemanCFOSell12,833$30.06$385,759.9827,833View SEC Filing  
11/20/2017Frederic H MollDirectorSell14,200$28.76$408,392.00247,124View SEC Filing  
11/16/2017Frederic H MollDirectorSell6,700$28.77$192,759.00247,124View SEC Filing  
11/10/2017Frederic H MollDirectorSell800$29.00$23,200.00253,824View SEC Filing  
11/6/2017Jeryl L HillemanCFOSell12,833$27.78$356,500.7427,833View SEC Filing  
10/16/2017Lisa D EarnhardtInsiderSell20,000$28.37$567,400.00View SEC Filing  
10/4/2017Jeryl L HillemanCFOSell12,833$29.96$384,476.68View SEC Filing  
9/25/2017Richard E KaufmanCOOSell13,639$28.97$395,121.83133,757View SEC Filing  
9/15/2017Lisa D EarnhardtInsiderSell20,000$30.19$603,800.00525,868View SEC Filing  
9/5/2017Jeryl L HillemanCFOSell12,833$31.05$398,464.6527,833View SEC Filing  
8/28/2017Richard E KaufmanCOOSell22,425$30.22$677,683.50149,821View SEC Filing  
8/15/2017Lisa D EarnhardtInsiderSell20,000$30.79$615,800.00525,868View SEC Filing  
8/4/2017Jeryl L HillemanCFOSell12,833$29.00$372,157.0027,833View SEC Filing  
7/25/2017Richard E KaufmanCOOSell12,500$28.25$353,125.00169,821View SEC Filing  
7/17/2017Lisa D EarnhardtInsiderSell20,000$29.03$580,600.00580,868View SEC Filing  
7/10/2017Jeryl L HillemanCFOSell12,835$27.18$348,855.3027,835View SEC Filing  
6/15/2017Lisa D EarnhardtInsiderSell20,000$26.10$522,000.00583,493View SEC Filing  
5/22/2017Richard E KaufmanCOOSell20,000$22.87$457,400.00182,321View SEC Filing  
5/15/2017Lisa D EarnhardtInsiderSell20,000$22.98$459,600.00600,868View SEC Filing  
4/20/2017Richard E KaufmanCOOSell1,250$17.25$21,562.50202,321View SEC Filing  
4/17/2017Lisa D EarnhardtInsiderSell20,000$16.06$321,200.00610,868View SEC Filing  
3/15/2017Lisa D EarnhardtInsiderSell20,000$15.02$300,400.00620,868View SEC Filing  
10/20/2016Richard E KaufmanCOOSell3,603$16.58$59,737.74194,571View SEC Filing  
10/17/2016Lisa D EarnhardtInsiderSell400$18.00$7,200.00557,268View SEC Filing  
9/7/2016Amy WolbeckVPSell28,664$15.83$453,751.1218,076View SEC Filing  
9/6/2016James StambaughVPSell4,000$16.00$64,000.0023,700View SEC Filing  
8/3/2016James StambaughVPSell3,977$17.00$67,609.0027,977View SEC Filing  
7/18/2016James StambaughVPSell5,000$15.33$76,650.0029,000View SEC Filing  
6/13/2016James StambaughVPSell500$14.38$7,190.0024,000View SEC Filing  
5/16/2016Kieran GallahueDirectorBuy8,000$12.64$101,120.008,000View SEC Filing  
4/27/2016Amy WolbeckVPSell2,000$20.01$40,020.007,700View SEC Filing  
4/20/2016Richard E KaufmanCOOSell3,603$18.86$67,952.58198,174View SEC Filing  
4/18/2016Lisa D EarnhardtCEOSell28,500$18.69$532,665.00581,368View SEC Filing  
3/21/2016Richard E KaufmanCOOSell3,603$16.51$59,485.53201,777View SEC Filing  
3/15/2016Lisa D EarnhardtCEOSell9,000$18.01$162,090.00561,368View SEC Filing  
3/14/2016Frederic H MollDirectorSell1,299$18.53$24,070.47252,078View SEC Filing  
3/8/2016Frederic H MollDirectorSell601$18.56$11,154.56253,377View SEC Filing  
2/22/2016Richard E KaufmanCOOSell3,603$18.65$67,195.95205,380View SEC Filing  
1/21/2016Richard E. KaufmanCOOSell7,206$17.93$129,203.58208,983View SEC Filing  
1/15/2016Lisa D. EarnhardtCEOSell12,500$19.26$240,750.00570,368View SEC Filing  
12/15/2015Lisa D EarnhardtCEOSell6,820$19.85$135,377.00574,868View SEC Filing  
11/16/2015Lisa D EarnhardtCEOSell6,818$18.00$122,724.00581,688View SEC Filing  
10/15/2015Lisa D EarnhardtCEOSell6,818$18.72$127,632.96588,506View SEC Filing  
9/15/2015Lisa D EarnhardtCEOSell6,818$25.99$177,199.82595,324View SEC Filing  
9/11/2015Frederic H MollDirectorSell10,000$25.21$252,100.00282,428View SEC Filing  
8/17/2015Lisa D EarnhardtCEOSell6,818$28.51$194,381.18View SEC Filing  
7/20/2015James StambaughVPSell12,000$30.52$366,240.00View SEC Filing  
7/15/2015Lisa D EarnhardtCEOSell19,318$29.62$572,199.16View SEC Filing  
6/15/2015Lisa D EarnhardtCEOSell19,318$29.30$566,017.40View SEC Filing  
5/8/2015James StambaughVPSell2,785$23.87$66,477.95View SEC Filing  
4/13/2015Amy WolbeckVPSell16,000$26.25$420,000.00View SEC Filing  
4/1/2015James StambaughVPSell8,343$25.50$212,746.50View SEC Filing  
3/16/2015Lisa D EarnhardtInsiderSell19,318$23.56$455,132.08View SEC Filing  
3/11/2015Amy WolbeckVPSell8,000$23.06$184,480.00View SEC Filing  
3/9/2015James StambaughVPSell8,343$23.02$192,055.86View SEC Filing  
2/17/2015Lisa D EarnhardtInsiderSell19,318$22.69$438,325.42View SEC Filing  
2/12/2015Amy WolbeckVPSell8,000$22.12$176,960.00View SEC Filing  
2/2/2015James StambaughVPSell8,343$20.98$175,036.14View SEC Filing  
1/26/2015Robert H Binney JrVPSell6,300$21.18$133,434.00View SEC Filing  
9/11/2014Cynthia L LuccheseDirectorBuy5,000$17.11$85,550.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Intersect ENT (NASDAQ XENT) News Headlines

Source:
DateHeadline
Intersect ENT (XENT) Receives Average Recommendation of "Buy" from AnalystsIntersect ENT (XENT) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 20 at 3:40 AM
Zacks: Analysts Expect Intersect ENT (XENT) Will Post Quarterly Sales of $28.02 MillionZacks: Analysts Expect Intersect ENT (XENT) Will Post Quarterly Sales of $28.02 Million
www.americanbankingnews.com - May 20 at 3:06 AM
Notable Friday Option Activity: XENT, LGIH, ACHCNotable Friday Option Activity: XENT, LGIH, ACHC
www.nasdaq.com - May 18 at 4:51 PM
-$0.17 EPS Expected for Intersect ENT (XENT) This Quarter-$0.17 EPS Expected for Intersect ENT (XENT) This Quarter
www.americanbankingnews.com - May 18 at 1:43 PM
JPMorgan Says CMS Decision on Sinuva is Likely an Error Following Discussion with Management (XENT)JPMorgan Says CMS Decision on Sinuva is Likely an Error Following Discussion with Management (XENT)
www.streetinsider.com - May 12 at 9:50 AM
Jeryl L. Hilleman Sells 12,833 Shares of Intersect ENT (XENT) StockJeryl L. Hilleman Sells 12,833 Shares of Intersect ENT (XENT) Stock
www.americanbankingnews.com - May 7 at 7:40 PM
Intersect ENT (XENT) Stock Rating Reaffirmed by Canaccord GenuityIntersect ENT (XENT) Stock Rating Reaffirmed by Canaccord Genuity
www.americanbankingnews.com - May 7 at 4:26 PM
Q4 2018 EPS Estimates for Intersect ENT (XENT) Increased by William BlairQ4 2018 EPS Estimates for Intersect ENT (XENT) Increased by William Blair
www.americanbankingnews.com - May 7 at 4:16 AM
Intersect ENT (XENT) Raised to Buy at Zacks Investment ResearchIntersect ENT (XENT) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - May 5 at 3:13 PM
Brokers Set Expectations for Intersect ENTs Q2 2018 Earnings (XENT)Brokers Set Expectations for Intersect ENT's Q2 2018 Earnings (XENT)
www.americanbankingnews.com - May 4 at 5:50 AM
Q2 2018 EPS Estimates for Intersect ENT (XENT) Lifted by Leerink SwannQ2 2018 EPS Estimates for Intersect ENT (XENT) Lifted by Leerink Swann
www.americanbankingnews.com - May 4 at 5:50 AM
$28.05 Million in Sales Expected for Intersect ENT (XENT) This Quarter$28.05 Million in Sales Expected for Intersect ENT (XENT) This Quarter
www.americanbankingnews.com - May 3 at 8:42 AM
Intersect ENTs (XENT) Hold Rating Reaffirmed at Northland SecuritiesIntersect ENT's (XENT) Hold Rating Reaffirmed at Northland Securities
www.americanbankingnews.com - May 2 at 4:52 PM
Intersect ENT (XENT) Upgraded to "Strong-Buy" by ValuEngineIntersect ENT (XENT) Upgraded to "Strong-Buy" by ValuEngine
www.americanbankingnews.com - May 2 at 1:37 PM
Intersect ENT (XENT) Receives Hold Rating from BTIG ResearchIntersect ENT (XENT) Receives Hold Rating from BTIG Research
www.americanbankingnews.com - May 2 at 11:28 AM
Intersect ENTs (XENT) CEO Lisa Earnhardt on Q1 2018 Results - Earnings Call TranscriptIntersect ENT's (XENT) CEO Lisa Earnhardt on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 2 at 9:11 AM
Intersect ENT beats by $0.03, beats on revenueIntersect ENT beats by $0.03, beats on revenue
seekingalpha.com - May 2 at 9:11 AM
Edited Transcript of XENT earnings conference call or presentation 1-May-18 8:30pm GMTEdited Transcript of XENT earnings conference call or presentation 1-May-18 8:30pm GMT
finance.yahoo.com - May 2 at 9:11 AM
Intersect ENT (XENT) Earns "Overweight" Rating from JPMorgan ChaseIntersect ENT (XENT) Earns "Overweight" Rating from JPMorgan Chase
www.americanbankingnews.com - May 2 at 7:54 AM
Intersect ENT (XENT) Announces Quarterly  Earnings ResultsIntersect ENT (XENT) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 1 at 9:10 PM
Intersect ENT Reports First Quarter 2018 ResultsIntersect ENT Reports First Quarter 2018 Results
finance.yahoo.com - May 1 at 4:34 PM
Intersect ENT (XENT) Expected to Post Earnings of -$0.23 Per ShareIntersect ENT (XENT) Expected to Post Earnings of -$0.23 Per Share
www.americanbankingnews.com - May 1 at 1:10 AM
Intersect ENT (XENT) Given Consensus Rating of "Buy" by BrokeragesIntersect ENT (XENT) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 25 at 3:40 AM
Intersect ENT (XENT) to Release Earnings on MondayIntersect ENT (XENT) to Release Earnings on Monday
www.americanbankingnews.com - April 23 at 8:26 AM
Intersect ENT (XENT) Receives New Coverage from Analysts at Berenberg BankIntersect ENT (XENT) Receives New Coverage from Analysts at Berenberg Bank
www.americanbankingnews.com - April 20 at 11:55 AM
Intersect ENT (XENT) Insider Sells $593,850.00 in StockIntersect ENT (XENT) Insider Sells $593,850.00 in Stock
www.americanbankingnews.com - April 17 at 7:13 PM
Intersect ENT to Present at Deutsche Bank and Bank of America Merrill Lynch ConferencesIntersect ENT to Present at Deutsche Bank and Bank of America Merrill Lynch Conferences
finance.yahoo.com - April 17 at 5:05 PM
Intersect ENT (XENT) Rating Increased to Buy at BidaskClubIntersect ENT (XENT) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - April 17 at 9:57 AM
Intersect ENT to Report First Quarter 2018 Financial ResultsIntersect ENT to Report First Quarter 2018 Financial Results
finance.yahoo.com - April 16 at 4:35 PM
$23.68 Million in Sales Expected for Intersect ENT (XENT) This Quarter$23.68 Million in Sales Expected for Intersect ENT (XENT) This Quarter
www.americanbankingnews.com - April 16 at 5:03 AM
Intersect ENT (XENT) Given a $31.00 Price Target by Deutsche Bank AnalystsIntersect ENT (XENT) Given a $31.00 Price Target by Deutsche Bank Analysts
www.americanbankingnews.com - April 14 at 9:37 AM
Intersect ENT (XENT) Upgraded by TheStreet to C-Intersect ENT (XENT) Upgraded by TheStreet to C-
www.americanbankingnews.com - April 13 at 7:51 PM
Commit To Buy Intersect ENT At $30, Earn 9.7% Annualized Using OptionsCommit To Buy Intersect ENT At $30, Earn 9.7% Annualized Using Options
www.nasdaq.com - April 13 at 4:40 PM
Zacks Investment Research Reiterates "Hold" Rating for Intersect ENT (XENT)Zacks Investment Research Reiterates "Hold" Rating for Intersect ENT (XENT)
www.americanbankingnews.com - April 7 at 4:27 PM
Insider Selling: Intersect ENT Inc (XENT) CFO Sells 12,833 Shares of StockInsider Selling: Intersect ENT Inc (XENT) CFO Sells 12,833 Shares of Stock
www.americanbankingnews.com - April 4 at 10:56 PM
Intersect ENT (XENT) Stock Rating Lowered by BidaskClubIntersect ENT (XENT) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 4 at 12:55 PM
Intersect ENT Announces Launch of SINUVA™ Sinus Implant, a New In-Office Treatment Option for Recurrent Nasal ...Intersect ENT Announces Launch of SINUVA™ Sinus Implant, a New In-Office Treatment Option for Recurrent Nasal ...
www.businesswire.com - April 3 at 9:31 AM
Intersect ENT (XENT) Lifted to "Buy" at ValuEngineIntersect ENT (XENT) Lifted to "Buy" at ValuEngine
www.americanbankingnews.com - April 2 at 10:26 PM
Intersect ENT Announces Launch of SINUVA™ Sinus Implant, a New In-Office Treatment Option for Recurrent Nasal PolypsIntersect ENT Announces Launch of SINUVA™ Sinus Implant, a New In-Office Treatment Option for Recurrent Nasal Polyps
finance.yahoo.com - April 2 at 9:43 AM
Intersect ENTs (XENT) Hold Rating Reiterated at BTIG ResearchIntersect ENT's (XENT) Hold Rating Reiterated at BTIG Research
www.americanbankingnews.com - April 1 at 4:16 PM
Intersect ENT Inc (XENT) Receives Average Recommendation of "Buy" from BrokeragesIntersect ENT Inc (XENT) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - March 31 at 3:38 AM
$23.68 Million in Sales Expected for Intersect ENT Inc (XENT) This Quarter$23.68 Million in Sales Expected for Intersect ENT Inc (XENT) This Quarter
www.americanbankingnews.com - March 30 at 4:19 AM
Zacks: Brokerages Anticipate Intersect ENT Inc (XENT) Will Post Earnings of -$0.23 Per ShareZacks: Brokerages Anticipate Intersect ENT Inc (XENT) Will Post Earnings of -$0.23 Per Share
www.americanbankingnews.com - March 28 at 3:13 AM
Reviewing Reshape Lifesciences (RSLS) & Intersect ENT (XENT)Reviewing Reshape Lifesciences (RSLS) & Intersect ENT (XENT)
www.americanbankingnews.com - March 25 at 9:04 PM
Intersect ENT (XENT) Upgraded to "Buy" by BidaskClubIntersect ENT (XENT) Upgraded to "Buy" by BidaskClub
www.americanbankingnews.com - March 25 at 2:00 PM
Intersect ENT (XENT) Downgraded to "Hold" at BidaskClubIntersect ENT (XENT) Downgraded to "Hold" at BidaskClub
www.americanbankingnews.com - March 24 at 11:46 PM
Intersect ENT (XENT) Upgraded by BidaskClub to "Buy"Intersect ENT (XENT) Upgraded by BidaskClub to "Buy"
www.americanbankingnews.com - March 22 at 9:21 AM
Intersect ENT Inc (XENT) Insider Lisa D. Earnhardt Sells 15,000 SharesIntersect ENT Inc (XENT) Insider Lisa D. Earnhardt Sells 15,000 Shares
www.americanbankingnews.com - March 16 at 7:34 PM
Zacks: Brokerages Expect Intersect ENT Inc (XENT) Will Announce Earnings of -$0.23 Per ShareZacks: Brokerages Expect Intersect ENT Inc (XENT) Will Announce Earnings of -$0.23 Per Share
www.americanbankingnews.com - March 10 at 7:14 PM
Intersect ENT Inc (XENT) Receives Consensus Recommendation of "Buy" from AnalystsIntersect ENT Inc (XENT) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - March 6 at 3:28 AM

SEC Filings

Intersect ENT (NASDAQ:XENT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Intersect ENT (NASDAQ:XENT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Intersect ENT (NASDAQ XENT) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.